- Home
- GRRR vs ERAS Comparison
GRRR vs ERAS Comparison
Compare GRRR & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRRR
- ERAS
- Stock Information
- Founded
- GRRR 2001
- ERAS 2018
- Country
- GRRR United Kingdom
- ERAS United States
- Employees
- GRRR N/A
- ERAS N/A
- Industry
- GRRR Computer Software: Prepackaged Software
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- GRRR Technology
- ERAS Health Care
- Exchange
- GRRR Nasdaq
- ERAS Nasdaq
- Market Cap
- GRRR 387.9M
- ERAS 348.4M
- IPO Year
- GRRR N/A
- ERAS 2021
- Fundamental
- Price
- GRRR $25.90
- ERAS $1.37
- Analyst Decision
- GRRR Buy
- ERAS Strong Buy
- Analyst Count
- GRRR 1
- ERAS 6
- Target Price
- GRRR $18.00
- ERAS $4.83
- AVG Volume (30 Days)
- GRRR 2.0M
- ERAS 1.7M
- Earning Date
- GRRR 06-18-2025
- ERAS 08-11-2025
- Dividend Yield
- GRRR N/A
- ERAS N/A
- EPS Growth
- GRRR N/A
- ERAS N/A
- EPS
- GRRR N/A
- ERAS N/A
- Revenue
- GRRR $84,196,961.00
- ERAS N/A
- Revenue This Year
- GRRR $36.59
- ERAS N/A
- Revenue Next Year
- GRRR $30.68
- ERAS N/A
- P/E Ratio
- GRRR N/A
- ERAS N/A
- Revenue Growth
- GRRR 19.91
- ERAS N/A
- 52 Week Low
- GRRR $2.09
- ERAS $1.01
- 52 Week High
- GRRR $44.15
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- GRRR 67.95
- ERAS 46.81
- Support Level
- GRRR $18.14
- ERAS $1.31
- Resistance Level
- GRRR $20.34
- ERAS $1.59
- Average True Range (ATR)
- GRRR 2.06
- ERAS 0.13
- MACD
- GRRR 0.35
- ERAS -0.02
- Stochastic Oscillator
- GRRR 91.61
- ERAS 25.00
About GRRR Gorilla Technology Group Inc.
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.